Abstract: Provided is an anesthetic composition for locally administering a local anesthetic agent to a subject in need thereof. The anesthetic composition has a lipid based complex prepared by hydrating a lipid cake containing a local anesthetic agent and a lipid mixture with an aqueous buffer solution at a pH higher than 5.5. Also provided is a method to prepare an anesthetic composition using a simpler and more robust for large-scale manufacture and for providing a high molar ratio of local anesthetic agent to phospholipid content as compared to the prior art. This anesthetic composition has a prolonged duration of efficacy adapted to drug delivery.

Abstract: The present disclosure provides a semiconductor device and a method for forming a semiconductor device. The semiconductor device includes a substrate, and a first gate dielectric stack over the substrate, wherein the first gate dielectric stack includes a first ferroelectric layer, and a first dielectric layer coupled to the first ferroelectric layer, wherein the first ferroelectric layer includes a first portion made of a ferroelectric material in orthorhombic phase, a second portion made of the ferroelectric material in monoclinic phase, and a third portion made of the ferroelectric material in tetragonal phase, wherein a total volume of the second portion is greater than a total volume of the first portion, and the total volume of the first portion is greater than a total volume of the third portion.

Abstract: A method of fabricating a semiconductor structure includes the following steps. A semiconductor wafer is provided. A plurality of first surface mount components and a plurality of second surface mount components are bonded onto the semiconductor wafer, wherein a first portion of each of the second surface mount components is overhanging a periphery of the semiconductor wafer. A first barrier structure is formed in between the second surface mount components and the semiconductor wafer. An underfill structure is formed under a second portion of each of the second surface mount components, wherein the first barrier structure blocks the spreading of the underfill structure from the second portion to the first portion.

Abstract: A device detecting system is provided. The device detecting system includes a bar code scanner, a plurality of device accommodating spaces, a screen, and a server. The server obtains bar code information via the bar code scanner and opens one of the device accommodating spaces based on the bar code information to accommodate an electronic device. The server performs a test procedure on the electronic device to generate a test result, and displays the test result and operation information corresponding to the test result on the screen.

Abstract: A viewing angle switching module includes a first viewing angle controlling device, a second viewing angle controlling device, a first polarizer, and a second polarizer. The first viewing angle controlling device includes a first alignment layer, a second alignment layer, and a first liquid crystal layer. The second viewing angle controlling device includes a third alignment layer, a fourth alignment layer, and a second liquid crystal layer. The first polarizer is disposed on a side of the first viewing angle controlling device, and an axial direction of a first absorption axis thereof is perpendicular or parallel to a first alignment direction of the first alignment layer. The second polarizer is disposed on a side of the second viewing angle controlling device, and an axial direction of a second absorption axis thereof is perpendicular or parallel to a third alignment direction of the third alignment layer. A display apparatus including the same is also disclosed.

Abstract: A device detecting system is provided. The device detecting system includes a bar code scanner, a plurality of device accommodating spaces, a screen, and a server. The server obtains bar code information via the bar code scanner and opens one of the device accommodating spaces based on the bar code information to accommodate an electronic device. The server performs a test procedure on the electronic device to generate a test result, and displays the test result and operation information corresponding to the test result on the screen.

Abstract: A balloon catheter system assisted by ultrasound and microbubbles and a method for vasodilation are provided. The system includes: a controller; a sensor catheter; a highly focused ultrasound probe, and the highly focused ultrasound probe and the sensor catheter is connected to the controller; and a balloon catheter. The method of vasodilation includes: providing a sensor catheter into a blood vessel, and controlling a highly focused ultrasound probe to focus at a hardened portion of the blood vessel; removing the sensor catheter from the blood vessel and inserting a balloon catheter into the blood vessel; infusing microbubbles into the balloon catheter and controlling the highly focused ultrasound probe to start working to destroy a calcification point of the hardened portion of the blood vessel, and smoothly inflating the balloon catheter at the hardened portion of the blood vessel.

Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.

Abstract: The present invention provides a vortexed-acoustic-field method for creating cell permeability and opening blood-brain barrier, which comprises using an ultrasonic transducer; using a probe emitting a vortexed acoustic field, the probe emitting a vortexed acoustic field having a piezoelectric patch comprising at least one inner channel, where when there is a plurality of inner channels, a phase difference is generated between each two channels, which is used by the ultrasonic transducer to generate a vortex in an acoustic channel; and generating a vortexed acoustic field to enable the cells to have permeability, where the vortexed acoustic field has the following parameters: frequency: 20 kHz to 20 MHz, and acoustic pressure: 0.1 to 10 MPa.

Abstract: Provided is an anesthetic composition for locally administering a local anesthetic agent to a subject in need thereof. The anesthetic composition has a lipid based complex prepared by hydrating a lipid cake containing a local anesthetic agent and a lipid mixture with an aqueous buffer solution at a pH higher than 5.5. Also provided is a method to prepare an anesthetic composition using a simpler and more robust for large-scale manufacture and for providing a high molar ratio of local anesthetic agent to phospholipid content as compared to the prior art. This anesthetic composition has a prolonged duration of efficacy adapted to drug delivery.

Abstract: An organic nanofiber includes a fiber body containing multiple inorganic oxide particles selected from polycrystalline titanium dioxide particles and polycrystalline tin(IV) oxide particles, and having a particle size ranging from 15 to 75 nm. A method for manufacturing the inorganic nanofibers, including: mixing a metal precursor, an organic polymer and a solvent to obtain a solution, the metal precursor being a titanium-containing precursor or a tin-containing precursor; electrospinning the solution at a relative humidity ranging from 50 to 60% to form multiple nanofibers; and annealing the nanofibers at a temperature ranging from 600 to 800° C. to obtain multiple inorganic nanofibers.

Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.

Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.

Abstract: An organic nanofiber includes a fiber body containing multiple inorganic oxide particles selected from polycrystalline titanium dioxide particles and polycrystalline tin(IV) oxide particles, and having a particle size ranging from 15 to 75 nm. A method for manufacturing the inorganic nanofibers, including: mixing a metal precursor, an organic polymer and a solvent to obtain a solution, the metal precursor being a titanium-containing precursor or a tin-containing precursor; electrospinning the solution at a relative humidity ranging from 50 to 60% to form multiple nanofibers; and annealing the nanofibers at a temperature ranging from 600 to 800° C. to obtain multiple inorganic nanofibers.

Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.

Abstract: The amino acid sequence of a biologically active polypeptide hormone isolated from calf thymus termed thymosin .alpha..sub.1 has been determined. Thymosin .alpha..sub.1 is a heat stable acidic molecule composed of 28 amino acid residues. This peptide is one of several present in thymosin fraction 5 which participate in the regulation, differentiation and function of thymic dependent lymphocytes (T cells).